Patent & Trade Mark
Jess Gledhill
Jess Gledhill

Level 23, 44 Market St
Tel +61 2 8231 1057
Fax +61 2 8231 1099
Recent Publications
28 Jul 2015
Often, a pharmaceutical does not earn revenue for a company until well into the patent term; sometimes this may be 15 years or more into the term. This delay, coupled with the cost of drug development recently estimated to be on average US$2.6 billion, it is not surprising that pharmaceutical companies seek to extend patent protection for as long as possible to maintain their market exclusivity. While follow-on patenting is sometimes portrayed as an abuse of the patent system by pharmaceutical companies, recent reports found that follow-on patents are not solely held by originator companies and that generic companies also typically file these types of patents.

23 Jan 2015
In a 7-2 decision, the Supreme Court has held that an “appellate court [Court of Appeals for the Federal Circuit] must apply a 'clear error,' not de novo, standard of review” to the factual aspects of evidentiary underpinnings of a District Court's claim construction determination. The Court grounded its decision in Federal Rule of Civil Procedure 52(a)(6), which provides that in matters tried to District Court, the court's “[f]indings of fact . . . must not be set aside unless clearly erroneous.”

Jess is known for building strong relationships with clients while providing them with comprehensive technical advice on their intellectual property portfolios. Her expertise lies in delivering commercially viable patentability advice, and advising clients on freedom-to-operate and patent landscapes issues.

Jess acts for a wide range of local and global clients in the chemistry space, including universities, research institutes and listed companies. She has extensive experience working with pharmaceutical and biotechnology companies, integrating intellectual property advice with their commercial strategy.

Jess has particular expertise and interest in small molecules. She completed her PhD in organic chemistry at The University of Adelaide having conducted research on potential anti-cancer agents. Her research involved the development of novel small molecule heteroaromatic inhibitors of SH3 domains; protein domains found in a variety of cell-signalling proteins.
Jess has held a number of Postdoctoral appointments including a position at the biotech company Avexa Ltd developing heterocyclic molecules for Hepatitis C and HIV and an appointment at Monash University working on supramolecular systems. Before joining the patent profession, Jess was also an OCE Postdoctoral fellow at CSIRO Materials Science and Engineering researching peptidomimetics for haemopoetic stem cell therapy.

Jess joined FB Rice in 2011 and is a registered Australian and New Zealand Patent Attorney in the Sydney Chemistry group.


  • Bachelor of Science (Hons) in Chemistry and Biochemistry & Molecular Biology from James Cook University
  • PhD in Organic Chemistry from the University of Adelaide

Key Areas of Expertise

  • Chemistry
  • Medicinal chemistry
  • Organic chemistry
  • Nanotechnology
  • Supramolecular chemistry
  • Pharmaceuticals
  • Biochemistry
  • Molecular biology
  • Biotechnology

Industry Focus

Professional Affiliations

  • Member of the Royal Australian Chemical Institute
  • Member of the American Chemical Society